| Transparent Cap-assisted SpyGlass for Biliary Stricture (NCT05320497) | Affiliated Hospital to Academy of Military Medical Sciences | 2022-04-14 |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). (NCT04566133) | National Cancer Institute (NCI) | 2022-02-15 |
| TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer (NCT05190575) | Shanghai Zhongshan Hospital | 2022-01-14 |
| A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up (NCT05237193) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2021-09-03 |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (NCT04956640) | Eli Lilly and Company | 2021-07-19 |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (NCT04579380) | Seagen, a wholly owned subsidiary of Pfizer | 2021-01-11 |
| LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent (NCT04595058) | Hospital Universitari de Bellvitge | 2020-11-17 |
| A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection (NCT04856761) | Fudan University | 2020-11-01 |
| Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (NCT04584008) | Peking University | 2020-09-23 |
| Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies (NCT04566614) | Royal Marsden NHS Foundation Trust | 2020-06-18 |
| Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (NCT04308174) | Asan Medical Center | 2020-05-20 |
| Primary Hepatobiliary Cancer Cohort of Central China (NCT05520801) | Tongji Hospital | 2020-05-01 |
| Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors (NCT04010071) | Peking Union Medical College Hospital | 2020-05-01 |
| Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (NCT03875235) | AstraZeneca | 2019-04-16 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers (NCT03801083) | Udai Kammula | 2019-02-19 |
| Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (NCT03478488) | 3D Medicines (Sichuan) Co., Ltd. | 2018-04-16 |
| Analgesic Efficacy After Pancreatobiliary Surgery: Intravenous Versus Patient-controlled Epidural (NCT04352023) | National Cancer Center, Korea | 2018-01-01 |
| Apatinib for Advanced Biliary Carcinoma (NCT03427242) | Fudan University | 2017-11-01 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer (NCT03101566) | University of Michigan Rogel Cancer Center | 2017-09-08 |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) (NCT03111732) | National Cancer Institute (NCI) | 2017-06-14 |
| Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer (NCT03046862) | Seoul National University Hospital | 2017-02-25 |
| The Effect of Individualized Precision Therapy Programs in Patients With BTC (NCT02943031) | RenJi Hospital | 2016-12-01 |
| EUS BD vs ERCP TP for Pancreatic Cancer (NCT03063554) | Weill Medical College of Cornell University | 2016-10-18 |
| Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers (NCT02829918) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-05 |
| Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy (NCT02784353) | Asan Medical Center | 2016-10-04 |
| A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) (NCT02821754) | National Cancer Institute (NCI) | 2016-07-05 |
| The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer (NCT02809898) | RenJi Hospital | 2016-07-01 |
| Precise Treatment in Hepatobiliary Cancers (PTHBC) (NCT02715089) | Peking Union Medical College Hospital | 2015-12-01 |
| Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures (NCT02615210) | Temple University | 2015-11-01 |
| Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer (NCT02558959) | Zhejiang University | 2015-09-01 |
| Evolution® Biliary Stent System Clinical Study (NCT01962168) | Cook Group Incorporated | 2013-12-01 |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma (NCT01950572) | National Cancer Institute (NCI) | 2013-09-09 |
| Tremelimumab With Chemoembolization or Ablation for Liver Cancer (NCT01853618) | National Cancer Institute (NCI) | 2013-05-02 |
| Radiofrequency Ablation for Malignant Biliary Obstruction (NCT01758341) | Medical University of Vienna | 2012-12-01 |
| Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy (NCT01731821) | Fudan University | 2012-10-01 |
| ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer (NCT01242605) | University College, London | 2012-02-01 |
| Endoscopic Therapy of Malignant Bile Duct Strictures (NCT01543607) | Massachusetts General Hospital | 2012-02-01 |
| Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy (NCT01695447) | TingBo Liang | 2012-01-01 |
| Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers (NCT00939848) | University College, London | 2011-04-01 |
| Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents (NCT01315522) | Seoul National University Hospital | 2010-06-01 |
| The Diagnostic Value of Combinatory EUS and ERCP in Unclear Lesions (NCT03504293) | Sahlgrenska University Hospital | 2010-01-01 |
| RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction (NCT00980889) | Stockholm South General Hospital | 2009-05-01 |
| Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer (NCT00487851) | Karolinska Institutet | 2007-03-01 |
| Endoscopic Stenting of Gastrointestinal Cancer (NCT00422409) | Ullevaal University Hospital | 2006-10-01 |
| A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy (NCT00359320) | Thomas Jefferson University | 2006-05-25 |
| Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes (NCT07252570) | Centre Hospitalier Universitaire de Nice | 2004-04-08 |
| Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) (NCT00196105) | Cook Group Incorporated | 2003-09-01 |
| EXIBIT: Oxaliplatin in Biliary Tract Cancer (NCT00174564) | Sanofi | 2003-04-01 |
| The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer (NCT00268840) | ARCAGY/ GINECO GROUP | 2001-08-01 |